[Skip to Content]
[Skip to Content Landing]
November 19, 2014

Searching for Treatments of Heart Failure With Preserved Ejection Fraction: Matching the Data to the Question

Author Affiliations
  • 1Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2014;312(19):1977-1978. doi:10.1001/jama.2014.15358

Heart failure with preserved ejection fraction (HFPEF) poses just as daunting a challenge for physicians and patients as heart failure with reduced ejection fraction (HFREF) but without nearly as defined a course for how to best treat affected patients. Although potential new therapies for treating HFPEF are being investigated, it is always worth revisiting existing therapies to evaluate their potential as available and cost-effective options for care. This sentiment has motivated several studies of β-blockers and their association with important outcomes for patients with HFPEF,1,2 including the observational analysis by Lund and colleagues3 in this issue of JAMA.